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Available online 29 June 2016AbstractBackground: Cutaneous metastases represent a therapeutic challenge. An increasing body of experience suggests that electrochemotherapy
(ECT) provides effective tumor control, although its evidence basis should be strengthened.
Methods: This prospective, multicenter, observational study enrolled patients with superficial metastases, who underwent ECT at 10 centers
between 2008 and 2013. Outcomes included adherence to European Standard Operating Procedures of ECT (ESOPE), tumor response,
local progression-free survival (LPFS), toxicity and patient-reported outcomes (PROs, EORTC QLQ-C30 plus an 8-item questionnaire).
Results: We enrolled 376 eligible patients. Tumor histotype distribution was as follows: melanoma, 56%; squamous cell carcinoma, 11%;
Kaposi sarcoma, 11%; breast carcinoma, 8%; basal cell carcinoma, 6%; soft tissue sarcomas, 3%; others, 5%. We registered 1304 target
tumors (median size 1 cm). Treatment adhered to ESOPE in 88% of patients as to the route of drug administration, and in 70% as to elec-
trode application. The procedure was mainly performed under sedation (64.6%) and by using intravenous chemotherapy (93.4%). Tumor
response rate at 60 days was 88% (complete, 50%). Small tumor size predicted complete response achievement (OR 2.24, p ¼ 0.003),
higher LPFS (HR 0.68, p ¼ 0.004) and improved PROs (Global Health Status, p < 0.001; wound bleeding, p < 0.001; healing,
p ¼ 0.002; and aesthetics, p < 0.001). Skin toxicity (grade 3, 7.8%) was lower in patients with tumors <2 cm ( p 0.001). One-year
LPFS was 73.7% (95%CI 68.4e78.3).
Conclusions: ECT represents a valuable skin-directed therapy across a range of malignancies. The most frequently applied treatment mo-
dality is intravenous chemotherapy under sedation. Small tumor size predicts durable tumor control, fewer side-effects and better PROs.
 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
Keywords: Electrochemotherapy; Cutaneous metastases; Melanoma; Breast cancer; Squamous cell carcinoma; Basal cell carcinomahor. Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy.
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Skin metastases are a relatively uncommon (0.6%e
10.4%) though distressing problem in cancer patients.1
They occur in up to 20% of melanoma patients, and, in
half cases, represent the first site of progression.2 Non-
cutaneous malignancies account for 10% of skin metasta-
ses, and are most commonly observed in breast cancer pa-
tients.3 This condition can be highly symptomatic, due to
necrotic evolution and ulceration, which may cause both
physical and psychological discomfort.4 Systemic and lo-
coregional therapies or radiation represent the mainstay of
treatment, nevertheless these options are often unfeasible,
due to development of tumor resistance or deterioration
of patient performance status (PS). Alternatives include
photodynamic, intralesional and topical therapies, all of
which have shown a variable degree of efficacy, although
standardized protocols for optimizing their application are
still lacking.5e7 During the last two decades, a new treat-
ment modality has been developed, combining transient tu-
mor permeabilization (i.e. reversible electroporation) e
obtained by means of properly tuned electric pulses e com-
bined with cytotoxic agents (electrochemotherapy, ECT).8,9
In ECT, electric pulses open transient pores on the cell
membrane and propel drug molecules into the cytosol. Its
principal advantage is local dose intensity, in fact high in-
tratumoral drug concentration is achieved and cytotoxicity
is increased by w8000 fold for bleomycin and by w80
fold for cisplatin.10e12 Since early 90s, ECT emerged as a
local treatment for superficial tumors.13 There is now an
increasing wealth of evidence that ECT, with either bleo-
mycin or cisplatin, is efficacious across malignancies.14e16
However, the procedure was standardized only in 2006,
based on a multicenter European study on 61 patients,10
whose clinical protocol has been subsequently adopted as
the European Standard Operative Procedures of Electroche-
motherapy (ESOPE).17 Two meta-analyses have confirmed
sustained antitumor activity for ECT.5,18 Compared with
conventional options, ECT has some advantages. It can
be administered in one day; it is well tolerated and can
be repeated; the majority of subjects have their tumor
controlled locally. On this basis, the National Institute for
Health and Care Excellence (NICE) has recently incorpo-
rated ECT into the multidisciplinary management of pa-
tients with skin metastases (interventional procedure
guidance IPG446 e “Electrochemotherapy for metastases
in the skin from tumors of non-skin origin and melanoma”),
although supporting literature has weaknesses in both
methodology and reporting.19e21 Such conflicting consider-
ations prompted us to launch the present multi-institutional
study. After the ESOPE experience, no other multicenter
study has been performed. Thus, the main goal was to
confirm the ESOPE results, in a large real-world series
and in a prospective setting, as well as to identify factors
affecting patient outcome. Secondary aims were to describe
the applied treatment modalities and to assess adherence toESOPE. Finally, we collected data on tumor control and pa-
tient reported outcomes (PROs).
Patients and methodsStudy managementThis was a prospective, multicenter, single-arm, investi-
gator-led observational cohort study promoted by the Ital-
ian Melanoma Intergroup (IMI) and the Italian Group of
Dermato-Oncology (GIDO), and supported by Igea Spa,
Carpi, Modena, Italy. Study supervision was directed by a
steering committee of clinical investigators. The sponsor
had no access to the data and no role in the preparation
of this report. The institutional review board of each center
approved the study and patient management conformed the
rules of Good Clinical Practice.Study populationWe prospectively enrolled all the consecutive patients
who underwent ECT from October 2008 through March
2013 at ten Italian centers (Fig. 1). Study follow-up was
concluded on August 2014. Eligible patients were at least
18 years of age, had cutaneous/subcutaneous histologically
confirmed metastases from cancer of any histotype, primary
or recurrent basal cell carcinoma (BCC) or squamous cell
carcinoma (SCC), had measurable disease, were unrespon-
sive to or unsuitable for conventional treatments, had tumor
nodule(s) smaller than 3 cm in thickness and not deeper
than 3 cm. Additional inclusion criteria were: no concomi-
tant treatments one month before and two months following
ECT, a 0e2 Eastern Cooperative Oncology Group (ECOG)
PS score, a life expectancy of at least three months, normal
hematologic, hepatic and renal function. Patients were
excluded if they had abnormal respiratory function, a car-
diac pacemaker or arrhythmias, previous maximal exposure
to bleomycin, or history of seizures.Tumor registrationFor each patient, a maximum of seven tumors were
registered as target lesions and the sum of their largest di-
ameters was used as a baseline value for subsequent
response assessment.ProcedureECTwas planned as a day-case procedure, unless patient
comorbidities indicated otherwise. The anesthesiology
technique was derived from the ESOPE, but adaptations
were allowed according to local protocols. The ESOPE
was strictly recommended for ECT treatment and its adher-
ence was defined as the rate of patients in whom the recom-
mended route of drug administration and electrode type
were used (Supplementary Table 1); recommendations
Figure 1. Study flow chart.
1916 L.G. Campana et al. / EJSO 42 (2016) 1914e1923were extrapolated from the flow chart of the original
ESOPE publication.17 The patients received intravenous
or intratumoral chemotherapy, followed by the application
of electric pulses by means of a suitable electrode,22 con-
nected to a Cliniporator device. The choice between
intravenous vs intratumoral chemotherapy was based on
the number and size of tumor nodules. Indicatively, less
than 20 small (i.e., <0.8 cm), not scattered tumor nodules,
or less than 7 tumor nodules between 0.8 and 2 cm in size
were indication of intratumoral drug (bleomycin or
cisplatin) injection. The remaining patients were given
intravenous bleomycin. The four operating modalities
were defined by combining the type of anesthesia and the
route of drug administration.17Patient follow-up and assessmentAfter treatment, follow-up visits were planned at two
weeks and then at 1, 2, 3, 6 and 12 months. At each visit,
data were collected on local response, treatment failure,
toxicity and PROs. Tumor response was clinically assessed
according to the Response Evaluation Criteria in solid Tu-
mors,23 adverse events according to the Common Terminol-
ogy Criteria for Adverse Events (CTCAE v3.0).
Accordingly, complete response (CR) was the disappear-
ance of all target lesions, partial response (PR) a decrease
of at least 30% in the sum of the longest diameters of target
lesions, progressive disease (PD) was an increase of at least
20% in the sum of the longest diameters of target lesions;
finally, stable disease (SD) was neither sufficient tumor
shrinkage to qualify for PR nor sufficient increase to
qualify for PD.
Additional ECT and oncological treatments were al-
lowed after two months. PROs were assessed by means
of the European Organization for Research and Treatmentof Cancer (EORTC) Quality of Life Questionnaire QLQ-
C30 and an 8-item, self-compiled, disease-specific ques-
tionnaire, described in detail elsewhere.24Statistical analysisThe Clinical Trials and Biostatistics Unit at Veneto Insti-
tute of Oncology managed data collection. Site monitoring
visits were conducted to verify case report forms and
source data. Two of the authors (LGC, PQ) and three
external collaborators reviewed patient files. In case of con-
troversies, supplemental information was gained from the
referring center. Patient data were transcribed into an on-
line, encrypted database. The relationship between vari-
ables was assessed with c2 or Fisher’s exact test, as
appropriate. Local progression-free survival (LPFS) was
the interval between ECT and in-field tumor relapse or pro-
gression. LPFS estimates were calculated using the Ka-
planeMeier method and compared with the log-rank test.
Multivariable analysis was performed using the Cox pro-
portional hazards regression method. A stepwise variable
selection procedure was applied to identify a subset of co-
variates for the final model, considering all variables with a
p-value 0.05 at univariate analysis and testing also the
interaction terms. After checking the proportional hazards
assumption, Hazard Ratios (HRs) with the 95% confidence
intervals CIs, calculated according to the Wald method,
were computed. To evaluate the impact of predictors of
complete response, the odds ratios (ORs) and correspond-
ing 95% CI were estimated through a multivariable logistic
regression model. Patients’ quality of life was examined by
repeated measures ANOVAs with tumor size (2 cm vs
<2 cm) as between-subject factor and time (before treat-
ment and then 30 and 60 days after ECT) as within-subject
factor and their interaction. The compound symmetry was
Table 1
Baseline demographics.
Characteristics No. %
Patients included 376 100
Age at first ECT (years)
Median 71
Range (minemax) 24e100
Sex
Male 164 43.6
Female 212 56.4
BMI
Median 26
Range (minemax) 17e46
PS (ECOG)
0 175 46.5
1 144 38.3
2 57 15.2
Histotype
Melanoma 211 56.1
SCC 41 10.9
Kaposi 40 10.6
BC 31 8.2
BCC 24 6.4
STS 10 2.7
Other histotypesa 19 5.1
Distant metastases
Yes 144 38.3
Visceral 98 68.1
Other sitesb 46 31.9
Tumor locationc
Lower limb 168 44.7
Trunk 76 20.2
Head and neck 65 17.3
Upper limb 16 4.3
Multiple 51 13.6
No. of treated tumorsc
Median 3
Interquartile range 1e5
Tumor size (mm)c,d
Median 10
Interquartile range 6e20
Tumor depth
Hypodermis 349 92.8
Epidermis, dermis 27 7.2
Previous treatmentse
No 70 18.6
Yes 306 81.4
Type of previous treatmentf
Surgery 262 85.6
Chemotherapy 128 41.8
Radiotherapy 58 18.9
Immunotherapy/ILP 76 24.8
Legend: BMI, body mass index; PS, performance status; ECOG, Eastern
Cooperative Oncology Group; SCC, squamous cell carcinoma; BC, breast
cancer; BCC, basal cell carcinoma; STS, soft-tissue sarcomas; ILP, iso-
lated limb perfusion.
a Other histotypes: other skin carcinoma (n ¼ 4); sweat gland carcinoma
(n ¼ 3); gastric adenocarcinoma (n ¼ 3); not specified (n ¼ 3); lung adeno-
carcinoma (n ¼ 2); metatypical carcinoma (n ¼ 1); parotid gland adeno-
carcinoma (n ¼ 1); endometrial adenocarcinoma (n ¼ 1); bladder
adenocarcinoma (n ¼ 1).
b Lymph nodes, bone, soft tissue.
c Target lesion registered at baseline.
d Median tumor size considering all tumors treated (n ¼ 1304) according
to tumor histotypes was as follows: SCC, 30 mm (IQ range, 16e50);
1917L.G. Campana et al. / EJSO 42 (2016) 1914e1923chosen for the covariance structure. All statistical analyses
were performed using the SAS statistical package (SAS,
rel. 9.4; SAS Institute Inc., Cary, NC).
ResultsStudy populationWe enrolled 394 patients (Fig. 1). This report includes
376 eligible patients fulfilling the inclusion criteria (Table
1). The median time from the diagnosis of primary tumor
to ECT was 2 years (range, 0.5e52). Among melanoma
and breast cancer patients, visceral metastases were present
in 65/211 (30.8%) and 16/31 (51.6%), respectively. The to-
tal number of target lesions was 1304 (median 3 per patient,
Interquartile (IQ) range, 1e5), median size being 10 mm
(IQ range, 6e20).ProcedureTwo hundred eighty-seven (76.3%) patients underwent a
single ECT (Table 2). The remaining 89 (23.7%) patients
received from 2 up to 6 ECT courses on partially respond-
ing (n ¼ 27) or newly occurred tumors (n ¼ 62). Re-
treatment involved 124 of 1304 (9.6%) target lesions. As
to the route of drug administration, adherence to ESOPE
guidelines was 88% (range, 15.6e96.5% according to spe-
cific clinical scenarios), while as to the type of electrode
adherence was 70% (range, 8.7e76.5%) (Supplementary
Table 1). One-hundred seventy-seven (47.1%) subjects
received further oncological treatments after ECT,
including cytotoxic chemotherapy, immunotherapy and
radiation.Toxicity
Systemic
No treatment-related serious adverse events were re-
ported during the procedure; during anesthesia monitoring,
we observed grade 1 or 2 cardiac arrhythmia (atrial fibrilla-
tion or sinus bradycardia) in 15 patients. During the hospi-
tal stay, which lasted a median of 1 day (range, 1e4), 55/
394 (13.9%) patients developed mild constitutional symp-
toms. One patient developed grade 3 thrombocytopenia,
which was incidentally discovered and required no
intervention.
Local
Distribution of dermatological toxicity was reported in
361 patients: grade 0, 150 patients (41.5%); grade 1, 118STS, 15.5 mm (IQ range, 10e35); BC, 15 mm (IQ range, 10e35);
BCC, 15 mm (IQ range, 10e30); Kaposi sarcoma, 10 mm (IQ range,
7e20); melanoma, 10 mm (IQ range 5e15).
e Since occurrence of skin metastases.
f Also more than one previous treatment per patients.
Table 2
Treatment details (N ¼ 376 patients).
Characteristics No. %
Anesthesia
Local 48 12.8
General sedation 243 64.6
General anesthesiaa 77 20.5
Not known 8 2.1
Drug
i.v. BLM 351 93.4
i.t. BLM 23 5.9
i.t. CDDP 2 0.5
Operating modality (ESOPE)
Ab 7 1.9
Bc 41 10.9
Cd 18 4.8
De 302 82.7
Otherf 8 2.1
Electrode type
Needle, hexagonal array 284 75.5
Needle, linear array 72 19.1
Plate 13 3.5
Multiple electrodes 7 1.9
No of ECT cycles
1 287 76.3
2 72 19.1
3 13 3.5
4 3 0.8
6 1 0.3
Legend: i.v., intravenous; i.t., intratumoral; BLM, bleomycin; CDDP,
cisplatin; ESOPE, European Standard Operative Procedures of Electroche-
motherapy e see Mir, 2006 [ref. 17].
a Twenty-three patients received ECT during surgical intervention.
b Local anesthesia and i.t. chemotherapy.
c Local anesthesia and i.v. chemotherapy.
d General sedation/anesthesia and i.t. chemotherapy.
e General sedation/anesthesia and i.v. chemotherapy.
f Anesthesia not known and i.v. chemotherapy.
Table 3
Skin toxicity after electrochemotherapy according to patient characteristics
(n ¼ 361).
Variable No. of pts Toxicity (NCI-CTCAE v3.0) p-valuea
Grade 0e1 Grade 2e4
No % No %
Tumor Histotype e
Melanoma 211 158 74.9 53 25.1
Kaposi 40 37 92.5 3 7.5
SCC 35 21 60.0 14 40.0
BCC 17 17 100 0 e
BC 31 15 48.4 16 51.6
STS 10 7 70.0 3 30.0
Other histotype 17 13 76.5 4 23.5
Tumor Histotype 0.740
Melanoma 211 158 74.9 53 25.1
Non-melanoma 150 110 73.3 40 26.7
Tumor location 0.094
Head and neck 51 38 74.5 13 25.5
Trunk 75 51 68.0 24 32.0
Lower limb 168 124 73.8 44 26.2
Upper limb 16 10 62.5 6 37.5
Multiple 51 45 88.2 6 11.8
Max tumor size <0.001
<20 mm 155 130 83.9 25 16.1
20 mm 206 139 67.5 67 32.5
Legend: SCC, squamous cell carcinoma; BCC, basal cell carcinoma; BC,
breast cancer; STS, soft tissue sarcomas.
a Chi-square test.
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patients (6.4%); grade 4, 5 patients (1.4%). The occurrence
of toxicity was associated with tumor size >2 cm
( p< 0.001) (Table 3). One hundred sixty-three patients
(41.3%) reported skin pain, its severity being grade 2 or 3
in 12 (3%) and 4 (1%) cases, respectively. Five (1.3%) pa-
tients transiently required treatment with opioids. We did
not find any association between post-ECT pain and patient
characteristics or ECT parameters (data not shown). A fe-
male melanoma patient who received ECT in the axillary
region, in the field of previous lymph node dissection and
subsequent resections of soft tissue recurrences, developed
a motor and sensory neuropathy shortly after the procedure.
In particular, she reported paresthesias and pain in her up-
per extremity and weakness of shoulder abduction, which
lasted six months and required treatment with opioids, pre-
gabalin and tricyclic antidepressants. Intraprocedural elec-
tric current ranged from 1 to 3.5 A. Electrodiagnostic
study, performed after 1 month, was suggestive for axillary
neuropathy, while ulnar and radial sensory nerve conduc-
tion were normal.Tumor response
Efficacy data are presented in Table 4. The majority of
complete responses were observed by the time of the sec-
ond tumor assessment at 2 months (50.0% vs 30.1% at 1
month). Tumor size emerged as the exclusive predictor of
response at univariate analysis (Supplementary Table 2).
The rate of complete response was 62.1% in patients
with small (<2 cm) tumors compared with 41.5% in pa-
tients with larger tumors (OR 2.31, 95% CI 1.34e3.96,
p ¼ 0.002). Although not significant at statistical anal-
ysis, tumor response rate (and CR rate) at 60 days ac-
cording to histotype was as follows: breast cancer,
89.5% (36.8%); BCC, 88.9% (66.7%); Kaposi sarcoma,
88.9 (44.4%); SCC, 85.2% (40.7%); soft tissue sarcoma,
83.3% (83.3%); melanoma, 83.1% (53.7%); other histo-
types, 60% (30%). We did not observe any regression
on untreated tumors, consistent with lack of an abscopal
effect.
Local control
The rate of LPFS at one year was 73.7% (95% CI,
68.4e78.3), median LPFS was 28.3 months (range,
23.0e37.6) (Table 4, Fig. 2a). While univariate analysis
showed that PS, tumor histotype, tumor location, number
of tumors and tumor size significantly affected LPFS,
only PS ( p ¼ 0.004), tumor histotype ( p < 0.001), location
( p < 0.001) and size ( p ¼ 0.004) were significant
Table 4
Efficacy summary.
Local response No. %
At 30 days, per-tumor evaluationa
CR 371 37.6
PR 291 29.5
SD 287 29.1
PD 37 3.8
At 60 days, per-tumor evaluationb
CR 494 60.9
PR 141 17.4
SD 152 18.7
PD 24 3.0
At 30 days, per-patient evaluationc
CR 88 30.1
PR 133 45.5
SD 62 21.2
PD 8 2.7
Not evaluable 1 0.3
At 60 days, per-patient evaluationd
CR 113 50.0
PR 75 33.2
SD 30 13.3
PD 7 3.1
Not evaluable 1 0.4
End point Value
Follow-up
Median duration for
alive patients e months (range)
13.9 (0.4e63.2)
Local (in-field) progression-free survival
Median duration e months (95% CI) 28.3 (23.0e37.6)
1-year (95% CI) 73.7 (68.4e78.3)
Status at last f-up e No pts (%)
Dead 140 (37.2)
Alive 236 (62.8)
Overall survival
Median duration e months (95% CI) 34.6 (27.4e41.9)
1-year (95% CI) 80.0 (75.0e84.2)
Disease status at last follow-up e No pts (%)
Disease free 81 (34.3)
Alive with skin metastases 58 (24.6)
Alive with skin and visceral metastases 31 (13.1)
Alive with visceral metastases 58 (24.6)
Unknown 8 (3.4)
Appearance of new lesionse e No pts (%)
Yes 175 (46.5)
No 186 (49.5)
Unknown 15 (4.0)
a Assessed on 986/1304 (75.6%) of baseline tumors.
b Assessed on 811/1304 (62.2%) of baseline tumors.
c Assessed on 292/376 (77.7%) patients.
d Assessed on 226/376 (60.1%) patients.
e Metastases occurred outside ECT field.
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3). LPFS of patients who received intravenous chemo-
therapy was comparable to that of patients who received in-
tratumoral chemotherapy (Fig. 2b). Out-of-field metastases
occurred in 175 (46.5%) patients. In the melanoma sub-
group, there were 25 (11.8%) subjects (18 with lower
limb tumors) who did not develop out-of-field recurrence.
Overall, 156 (41.5%) patients developed distant, non-skin,
disease progression.Quality of life
Two hundreds and eleven patients (56%) compiled the
EORTC QLQ-C30 (Table 5) at baseline, 30 and 60 days
from ECT treatment. The Global Health Status score pro-
gressively increased from 59.6 (baseline) to 64.7 (1 month),
up to 65.7 (2 months) ( p < 0.001). We observed a lower
score in patients with tumors 2 cm, compared with those
with tumors <2 cm ( p ¼ 0.018); nonetheless, a significant
increase after ECT was observed in both these groups
( p < 0.001, Supplementary Table 4). The scores of the
five functional scales did not changed after ECT as well
as those of the symptom scales. Among the six symptom
single-item scales, a statistically significant improvement
was observed only in the Constipation scale ( p ¼ 0.027).
One hundred and seventy-nine patients (47.6%)
compiled the 8-item questionnaire (Supplementary Table
5). Among the investigated items, the scores of wound
bleeding ( p < 0.001), healing ( p ¼ 0.002), and aesthetics
( p < 0.001) showed a statistically significant improvement.
The percentage of patients who stated that they would have
accepted re-treatment, if required, was 79.3% (142/179)
and 82.7% (148/179) at 1 and 2 months, respectively
(Supplementary Table 6). The acceptance rate was higher
in those with small tumors compared with those with larger
tumors at one-month assessment (89.2% vs 72.4%,
p ¼ 0.006), but rates were similar at two-month evaluation
(86.5 vs 80.0%, p ¼ 0.259).
Discussion
This multicentric study, which is based on the largest
prospective series published so far, strongly supports the ef-
ficacy of ECT in patients with superficial metastases from
any histotype and skin cancers. ECT yielded sustained
and durable response, with contained toxicity; furthermore,
it appeared to preserve and, in some cases, positively influ-
ence health-related quality of life outcomes. Ultimately,
this turned into a high acceptance rate by patients. As the
number of involved centers increases, and multicenter trials
are advocated to support ECT evidence basis, it is crucial to
reach a consensus on patient selection, treatment applica-
tion as well as to collect reliable outcome data in order to
inform patients.19
Overall, despite some discrepancies, clinicians had a
high level of adherence to the ESOPE protocol. In partic-
ular, in patients with more than 5 tumors (in whom intrave-
nous chemotherapy is recommended) and in those with
tumors 0.8 cm (in whom the hexagonal needle electrode
is recommended), the adherence rate was 76.5% and
96.6%, respectively. According to our experience, the ma-
jority of ECT candidates can safely undergo the procedure
under general sedation, thus confirming that this treatment
is well tolerated and easily manageable from the anesthesi-
ology point of view. In 20% of cases, ECT was carried out
under general anesthesia, since treatment was applied intra-
operatively, i.e., during major surgical procedures.
Figure 2. Local progression-free survival (LPFS) of patient with cutaneous metastases or skin cancers after electrochemotherapy. (a) LPFS of the entire study
cohort. (b) LPFS according to the route of drug administration. Legend: BLM, bleomycin; CDDP, cisplatin; i.v., intravenous; i.t., intratumoral.
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grade 3 adverse events being under 8%. These outcomes
compare well with previous reports on ECT in mela-
noma25,26 and breast cancer,20 and also with other skin-
directed treatments (e.g., photodynamic, intralesional andTable 5
Quality of life outcomes after electrochemotherapy (EORTC QLQ-C30a).
Electrochemotherapy (N ¼ 211 patients)
Scale Baseline mean  SD 30 day
Global health status
Global health status 59.56  22.83 64:73
Functional scales
Physical functioning 75.38  22.04 76.34
Role functioning 78.04  25.29 78.04
Emotional functioning 76.59  21.71 78.37
Cognitive functioning 90.32  16.67 90.92
Social functioning 85.48  22.40 87.04
Symptom scales
Fatigue 20.01  20.37 21.85
Nausea/vomiting 3.00  8.99 1.89 
Pain 22.75  24.37 22.04
Dyspnea 10.21  18.55 10.00
Insomnia 21.17  24.66 19.77
Appetite loss 9.05  17.18 9.05 
Constipation 11.59  21.83 8:73 
Diarrhea 2.07  9.86 1.26 
Financial problems 6.67  15.57 6.51 
)
p-value for ANOVA with Greenhouse-Geisser correction.
Comparison on each measure were made at three time points, using repeated meas
Mauchly’s test was executed to verify the assumption of sphericity and adjusted F
not meet.
Bonferroni’s test for multiple comparison was used to test for significant differen
Bonferroni procedures is the best one to use in terms of type I error control).
a The EORTC QLQ-C30 is a cancer-specific, self-administered 30-question ins
are grouped into five functional scales (physical functioning, role functioning, e
symptom scales (fatigue, nausea and vomiting, and pain); six symptom single-item
cial difficulties), and one global health status (GHS)/QoL scale. Of the 30 items,
and 30, for global health status) are scored on modified seven-point linear analog s
scores ranging from 0 to 100 after linear transformation. Higher scores for the fun
better QoL, respectively, whereas higher scores in symptom scales represented atopical therapies), which are associated with grade 3
toxicity in less than 6% of patients.5e7
Although in small number, we observed that breast can-
cer histotype and in particular tumor size >2 cm were asso-
ciated with higher rates of skin toxicity (Table 3). Breasts mean  SD 60 days mean  SD p)
 21:27 65:67  22:87 <0.0001
 20.92 75.22  23.89 0.4541
 24.82 78.20  26.45 0.9833
 21.98 78.81  22.56 0.0770
 17.07 91.59  14.79 0.3793
 21.72 87.46  21.48 0.1715
 20.75 21.87  22.34 0.1695
6.63 2.45  8.49 0.2441
 23.35 20.06  24.29 0.1582
 18.74 10.27  17.96 0.9511
 24.33 19.68  25.55 0.5135
17.79 8.57  17.58 0.9143
17:95 9:21  19:29 0.0269
8.51 1.90  10.13 0.4527
14.76 6.89  17.66 0.7205
ures analysis of variance (ANOVA) with time point as within-subject factor.
test proposed by Greenhouse-Geisser was considered when sphericity did
ces in QOL scores over time since the sphericity condition is not met (the
trument for evaluating the QoL in cancer patients. The questionnaire items
motional functioning, cognitive functioning, and social functioning); three
scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and finan-
28 are scored on four-point Likert scales and the remaining two items (29
cales. Scores were derived from mutually exclusive sets of items, with scale
ctioning and GHS/QoL scales indicated a higher level of functioning and a
higher level of symptom.
1921L.G. Campana et al. / EJSO 42 (2016) 1914e1923cancer patients generally undergo ECT after several lines of
treatment, also including radiation, which may increase the
risk of toxicity, as suggested by a phase II study in women
with chest wall recurrence who were previously irradi-
ated.20 Large/widespread tumors are managed by means
of the hexagonal electrode, which allows treatment of
extensive skin surfaces; this, in turn, may induce tissue
ischemia, due to the strong vascular disrupting effect of
ECT.27 It is advisable that clinicians are aware of these
eventualities, since, when tumor necrosis and/or skin ulcer-
ation occur, timely surgical debridement and appropriate
wound dressing is required.20
Pain control represent another relevant aspect of post-
ECT management. In our study, 41% of patients reported
pain, even though it was judged moderate or severe only
in 3% and 1%, respectively. In the retrospective analysis
of 121 ECT patients treated at seven European centers,
moderate and severe pain were each reported by 13% of
subjects.28 This could be explained by the higher percent-
age (30%) of tumors in the head and neck region, the
larger tumor size (median, 2.3 cm) and the more frequent
application of local anesthesia (40% of patients),
compared with the present study. On a multivariate anal-
ysis, pretreatment pain, high electric current intensity
and diagnosis of melanoma or breast cancer were predic-
tors of severe post-procedural pain.28 We were not able
to confirm these findings on our data. Of note, a melanoma
patient who underwent ECT in the axillary region, in the
field of previous multiple surgeries, reported relevant mo-
tor and sensor neuropathy. We hypothesize that extensive
scarring may have altered local anatomy and possibly en-
trapped nerve fibers, thus making them vulnerable to
injury by needle electrodes.
We observed an 80% overall response rate, with nearly
half of patients achieving tumor regression after a single
application. These findings confirm the ESOPE experien-
cedwhere response rate also exceeded 80%, and results
of more recent reports.5,10,18,20e22,24,25,29e32 A comprehen-
sive meta-analysis including both pre- and post-ESOPE
studies indicates an 84.1% response rate, with 59.4% of
complete responses.18 Histotype-oriented studies, although
not comparative,19 indicate variable, but generally sus-
tained response rates: up to 90% in melanoma,25,26 ranging
from 17% to 90% in breast cancer,20,21,31 around 90% in
soft tissue sarcomas and up to 100% in Kaposi sar-
coma.29,33 In the latter tumor type, the introduction of
ECT (which yielded an 88.9% response rate with a
44.4% CR response rate in our study) seems particularly
welcome since there is no standard therapy policy and con-
ventional treatment options (i.e., radiation, intralesional
therapies, cytotoxic chemotherapy) have specific limita-
tions related to disease extension, number of skin metasta-
ses and myelotoxicity, respectively.33
Tumor size stood out as the exclusive predictor of tumor
shrinkage. The patients with tumors smaller than 2 cm were
2.3 times more likely to achieve complete tumor regressioncompared with patients with larger tumors. This observa-
tion is in line with previous reports25,26,34 and may have im-
plications for patient selection and their management (i.e.,
need for additional ECT cycles). While incipient reports on
ECT have focused on local response, more recent experi-
ences highlight that durable tumor control can also be
achieved.20,24e26,29,33 Accordingly, 1-year LPFS in our
study was 73.7% (Table 4, Fig. 2a), which compares well
with the 73e88% control rate reported in the ESOPE
trial.10 However, the cumulative incidence of out-of-field
recurrences was nearly 50%. These recurrences were
managed with additional ECT cycles, nonetheless two
different strategies could be pursued: the inclusion of treat-
ment safety margins around tumors,19 and the combination
of ECT with immune modulating agents.35,36 Interestingly,
a subgroup (w12%) of patients with lower limb melanomas
remained free from new metastases and exclusive treatment
with ECT ensured tumor control. This observation supports
our previous experience, suggesting that patients with lower
limbs in-transit metastases, particularly when small and
limited in number, represent suitable candidates for treat-
ment with ECT.25
Since cutaneous metastases generally portend a dismal
prognosis, it is crucial that applied treatments preserve
quality of life. According to the EORTC-QLQ C30, the
Global Health Status showed a statistically significant
improvement, while a collateral observation was the
improvement of the Constipation scale score (Table 5).
Interestingly, the 8-item questionnaire indicated a benefit
in the items exploring skin metastases-associated com-
plaints. Patient satisfaction was also confirmed by the
high acceptance rate for retreatment, which ranged to
80%. We are aware that statistical differences cannot be
automatically considered as clinically meaningful, never-
theless our results suggest that ECT does not deteriorate pa-
tient quality of life and that PROs deserve further
investigation. A single study explored PROs after ECT so
far. By administering the 8-item questionnaire to 35 mela-
noma patients, we found an improvement in wound heal-
ing, bleeding, esthetic impairment, and also in related
aspects, such as activities of daily living and social
relations.24
Our study has certain limitations. First, we included pa-
tients with heterogeneous malignancies and did not address
the issue of which tumors might be most sensitive or resis-
tant to ECT. Second, efficacy evaluation was focused on
target lesions and on first ECT cycle, while in recent years
evidence has accumulated that retreatment is beneficial in
partial responders and in out-of-field relapses.24,26 This is
usually the case of melanoma patients with in-transit metas-
tases, sarcoma patients with satellites, or breast cancer pa-
tients with lymphangitic tumor spread.1 Therefore, it would
be advisable that future studies include more details, such
as out-of-field failure rate, efficacy of retreatment, and the
effective number of ECT cycles required to achieve tumor
control.19 Another weakness was that tumor response was
1922 L.G. Campana et al. / EJSO 42 (2016) 1914e1923clinically assessed, and thus possibly overestimated.
Finally, it seems important to acknowledge that LPFS could
have been influenced by further oncologic treatments and
that PROs were partially investigated by means of a non-
validated instrument.
In conclusion, the clinical experience with ECT is
growing and the results are promising. However, due to
the lack of high quality supporting evidence, the role of
this treatment modality is yet to be fully defined. This
multi-institutional real-world study adds on the evidence
supporting skin-directed treatment with ECT in patients
with superficial metastases and should foster the planning
of well-designed (possibly comparative) trials.
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